Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions

Journal of Immunology

Volumn 180, Issue 9, 2008, Pages 6116-6131

  Robbins, Paul F ^a   Li, Yong F ^a   El Gamil, Mona ^a   Zhao, Yangbing ^a   Wargo, Jennifer A ^a   Zheng, Zhili ^a   Xu, Hui ^a   Morgan, Richard A ^a   Feldman, Steven A ^a   Johnson, Laura A ^a   Bennett, Alan D ^b   Dunn, Steven M ^b   Mahon, Tara M ^b   Jakobsen, Bent K ^b   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MediGene Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; AMINO ACID DERIVATIVE; GAMMA INTERFERON; HLA A ANTIGEN; INTERLEUKIN 2; MELAN A; PROTEIN CDR2BETA; PROTEIN CDR3ALPHA; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HLA A*02 ANTIGEN; HLA-A*02 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MART1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN VARIANT; T LYMPHOCYTE ACTIVATION; COMPLEMENTARITY DETERMINING REGION; GENETICS; IMMUNOLOGY; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; HLA-A ANTIGENS; HUMANS; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL;

EID: 44449128698     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.9.6116     Document Type: Article

References (48)

1. Davis, M. M., J. J. Boniface, Z. Reich, D. Lyons, J. Hampl, B. Arden, and Y. Chien. 1998. Ligand recognition by αβ T cell receptors. Annu. Rev. Immunol. 16: 523-544. (Pubitemid 28183375)
2. Manning, T. C., and D. M. Kranz. 1999. Binding energetics of T-cell receptors: correlation with immunological consequences. Immunol. Today 20: 417-422. (Pubitemid 29423484)
3. van der Merwe, P. A., and S. J. Davis. 2003. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 21: 659-684. (Pubitemid 37174544)
4. Rudolph, M. G., J. G. Luz, and I. A. Wilson. 2002. Structural and thermodynamic correlates of T cell signaling. Annu. Rev. Biophys. Biomol. Struct. 31: 121-149. (Pubitemid 34666828)
5. Savage, P. A., and M. M. Davis. 2001. A kinetic window constricts the T cell receptor repertoire in the thymus. Immunity 14: 243-252. (Pubitemid 32289289)
6. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107. (Pubitemid 26144250)
7. Zeh, H. J., 3rd, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994.
8. Trautmann, L., M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, and M. Bonneville. 2005. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J. Immunol. 175: 6123-6132. (Pubitemid 41508100)
9. + T cell populations specific for persistent DNA viruses. J. Exp. Med. 202: 1349-1361.
10. Kasibhatla, S., E. A. Nalefski, and A. Rao. 1993. Simultaneous involvement of all six predicted antigen binding loops of the T cell receptor in recognition of the MHC/antigenic peptide complex. J. Immunol. 151: 3140-3151. (Pubitemid 23282625)
11. Eisen, H. N. 2001. Specificity and degeneracy in antigen recognition: yin and yang in the immune system. Annu. Rev. Immunol. 19: 1-21. (Pubitemid 32368027)
12. Manning, T. C., C. J. Schlueter, T. C. Brodnicki, E. A. Parke, J. A. Speir, K. C. Garcia, L. Teyton, I. A. Wilson, and D. M. Kranz. 1998. Alanine scanning mutagenesis of an αβ T cell receptor: mapping the energy of antigen recognition. Immunity 8: 413-425. (Pubitemid 28196796)
13. Manning, T. C., E. A. Parke, L. Teyton, and D. M. Kranz. 1999. Effects of complementarity determining region mutations on the affinity of an α/β T cell receptor: measuring the energy associated with CD4/CD8 repertoire skewing. J. Exp. Med. 189: 461-470. (Pubitemid 29187368)
14. Chlewicki, L. K., P. D. Holler, B. C. Monti, M. R. Clutter, and D. M. Kranz. 2005. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J. Mol. Biol. 346: 223-239. (Pubitemid 40128317)
15. - T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J. Exp. Med. 194: 1043-1052.
16. Holler, P. D., L. K. Chlewicki, and D. M. Kranz. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4: 55-62. (Pubitemid 36104709)
17. Weber, K. S., D. L. Donermeyer, P. M. Allen, and D. M. Kranz. 2005. Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc. Natl. Acad. Sci. USA 102: 19033-19038. (Pubitemid 43049561)
18. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23: 349-354. (Pubitemid 41094424)
19. Chen, Y. T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918. (Pubitemid 27113936)
20. Purbhoo, M. A., D. H. Sutton, J. E. Brewer, R. E. Mullings, M. E. Hill, T. M. Mahon, J. Karbach, E. Jager, B. J. Cameron, N. Lissin, et al. 2006. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J. Immunol. 176: 7308-7316. (Pubitemid 43849031)
21. Zhao, Y., A. D. Bennett, Z. Zheng, Q. J. Wang, P. F. Robbins, L. Y. Yu, Y. Li, P. E. Molloy, S. M. Dunn, B. K. Jakobsen, et al. 2007. High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines. J. Immunol. 179: 5845-5854.
22. Dunn, S. M., P. J. Rizkallah, E. Baston, T. Mahon, B. Cameron, R. Moysey, F. Gao, M. Sami, J. Boulter, Y. Li, and B. K. Jakobsen. 2006. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 15: 710-721.
23. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352. (Pubitemid 24181083)
24. Marincola, F. M., Y. M. Hijazi, P. Fetsch, M. L. Salgaller, L. Rivoltini, J. Cormier, T. B. Simonis, P. H. Duray, M. Herlyn, Y. Kawakami, and S. A. Rosenberg. 1996. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother. Emphasis Tumor Immunol. 19: 192-205. (Pubitemid 26234613)
25. Naviaux, R. K., E. Costanzi, M. Haas, and I. M. Verma. 1996. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70: 5701-5705. (Pubitemid 26240755)
26. Riker, A. I., U. S. Kammula, M. C. Panelli, E. Wang, G. A. Ohnmacht, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 2000. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int. J. Cancer 86: 818-826. (Pubitemid 30350197)
27. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59. (Pubitemid 19125653)
28. Robbins, P. F., M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J. Huang, D. J. Powell, Jr., and S. A. Rosenberg. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173: 7125-7130. (Pubitemid 39628146)
29. Zhao, Y., Z. Zheng, C. J. Cohen, L. Gattinoni, D. C. Palmer, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2006. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13: 151-159. (Pubitemid 41763493)
30. Szymczak, A. L., C. J. Workman, Y. Wang, K. M. Vignali, S. Dilioglou, E. F. Vanin, and D. A. Vignali. 2004. Correction of multi-gene deficiency in vivo using a single "self-cleaving" 2A peptide-based retroviral vector. Nat. Biotechnol. 22: 589-594.
31. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16: 457-472. (Pubitemid 40647143)
32. Thomas, G. 2002. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 3: 753-766.
33. Topalian, S. L., D. Solomon, and S. A. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142: 3714-3725. (Pubitemid 19137511)
34. Robbins, P. F., M. El-Gamil, Y. Kawakami, E. Stevens, J. Yannelli, and S. A. Rosenberg. 1994. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54: 3124-3126. (Pubitemid 24208914)
35. Boulter, J. M., M. Glick, P. T. Todorov, E. Baston, M. Sami, P. Rizkallah, and B. K. Jakobsen. 2003. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 16: 707-711. (Pubitemid 37314399)
36. Chen, J. L., G. Stewart-Jones, G. Bossi, N. M. Lissin, L. Wooldridge, E. M. Choi, G. Held, P. R. Dunbar, R. M. Esnouf, M. Sami, et al. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201: 1243-1255. (Pubitemid 40629068)
37. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. (Pubitemid 35231542)
38. Johnson, L. A., B. Heemskerk, D. J. Powell, Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg. 2006. Gene transfer of tumorreactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177: 6548-6559. (Pubitemid 44628874)
39. Holler, P. D., and D. M. Kranz. 2003. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18: 255-264. (Pubitemid 36263000)
40. Kalergis, A. M., N. Boucheron, M. A. Doucey, E. Palmieri, E. C. Goyarts, Z. Vegh, I. F. Luescher, and S. G. Nathenson. 2001. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2: 229-234. (Pubitemid 33705999)
41. Kersh, G. J., E. N. Kersh, D. H. Fremont, and P. M. Allen. 1998. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 9: 817-826. (Pubitemid 29024461)
42. Krogsgaard, M., N. Prado, E. J. Adams, X. L. He, D. C. Chow, D. B. Wilson, K. C. Garcia, and M. M. Davis. 2003. Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol. Cell 12: 1367-1378. (Pubitemid 38037007)
43. Sami, M., P. J. Rizkallah, S. Dunn, P. Molloy, R. Moysey, A. Vuidepot, E. Baston, P. Todorov, Y. Li, F. Gao, et al. 2007. Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Protein Eng. Des. Sel. 20: 397-403. (Pubitemid 47428966)
44. Peggs, K. S., S. Verfuerth, A. Pizzey, N. Khan, M. Guiver, P. A. Moss, and S. Mackinnon. 2003. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375-1377. (Pubitemid 37338339)
45. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333: 1038-1044.
46. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22: 117-129.
47. Morris, E. C., A. Tsallios, G. M. Bendle, S. A. Xue, and H. J. Stauss. 2005. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. USA 102: 7934-7939. (Pubitemid 40781041)
48. Kessels, H. W., K. Schepers, M. D. van den Boom, D. J. Topham, and T. N. Schumacher. 2006. Generation of T cell help through a MHC class I-restricted TCR. J. Immunol. 177: 976-982. (Pubitemid 44036599)